Stock Analysis
PHC Holdings (TSE:6523) Full Year 2024 Results
Key Financial Results
- Revenue: JP¥353.9b (flat on FY 2023).
- Net loss: JP¥12.9b (loss widened by 300% from FY 2023).
- JP¥102 loss per share (further deteriorated from JP¥25.84 loss in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
PHC Holdings EPS Misses Expectations
Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 94%.
Looking ahead, revenue is forecast to stay flat during the next 3 years compared to a 6.3% growth forecast for the Medical Equipment industry in Japan.
Performance of the Japanese Medical Equipment industry.
The company's shares are down 3.7% from a week ago.
Risk Analysis
It's still necessary to consider the ever-present spectre of investment risk. We've identified 2 warning signs with PHC Holdings, and understanding them should be part of your investment process.
Valuation is complex, but we're helping make it simple.
Find out whether PHC Holdings is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About TSE:6523
PHC Holdings
Through its subsidiaries, offers medical devices, healthcare IT solutions, and life science products and services primarily in Japan.
Undervalued with adequate balance sheet.